Theriva Biologics, Inc. 8-K

What Happened

• On June 11, 2026, Theriva Biologics (TOVX) issued a press release disclosing that clinical and translational results from the Phase 1 trial of VCN-01 in head & neck squamous cell carcinoma (HNSCC) were published online first in Clinical Cancer Research. The open-label trial enrolled 20 adults with refractory or metastatic HNSCC who had progressed after prior therapies, including anti-PD-(L)1 agents. Patients were treated with intravenous VCN-01 plus durvalumab in three cohorts: Arm I (concomitant low dose, 6 pts; VCN-01 3.3E12 vp given 4 hours before durvalumab 1500 mg q4w), Arm II low dose (8 pts; VCN-01 3.3E12 vp given 14 days before durvalumab), and Arm II high dose (6 pts; VCN-01 1.0E13 vp given 14 days before durvalumab).

Key Details

• Trial size and dosing: 20 patients total; Arm I LD = 6 pts (3.3E12 vp), Arm II LD = 8 pts (3.3E12 vp), Arm II HD = 6 pts (1.0E13 vp).
• Efficacy (medians): Progression-free survival (PFS) — Arm I LD 1.6 months, Arm II LD 3.7 months, Arm II HD 2.1 months; Overall survival (OS) — Arm I LD 10.3 months, Arm II LD 15.5 months, Arm II HD 17.3 months.
• Pharmacodynamics/virology: Circulating PH20 (hyaluronidase) rose significantly after VCN-01, peaking day 3–8 and detectable to day 28 in 11 of 12 tested patients; viral genome in blood showed an immediate post-dose peak and a secondary peak on day 3–8, consistent with intratumoral replication.
• Tumor immunology: Post-treatment biopsies showed increased CD8 and IDO, decreased FoxP3/CD25/CTLA4 (fewer Tregs), and upregulation of PD-1/PD-L1 in most patients — PD-L1 increases correlated with patient survival.

Why It Matters

• The filing documents published Phase 1 data indicating VCN-01 can replicate in tumors, modify the tumor microenvironment, and increase immune infiltration and PD-L1 expression — biological signals that may explain the observed OS medians when combined with durvalumab.
• For investors, these results are early (small Phase 1 cohort, 20 patients) and not definitive proof of clinical benefit, but the translational biomarkers and a peer-reviewed publication add credibility and could support further clinical development, potential trial expansions, regulatory discussions, or partnership interest.